These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1242670)

  • 21. Serum cystatin C is a better marker of topotecan clearance than serum creatinine.
    Hoppe A; Séronie-Vivien S; Thomas F; Delord JP; Malard L; Canal P; Chatelut E
    Clin Cancer Res; 2005 Apr; 11(8):3038-44. PubMed ID: 15837759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A simple method to estimate the initial dose of gentamicin.
    Lackner TE; Lyss AP
    Pharmacotherapy; 1992; 12(3):195-200. PubMed ID: 1608852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of simulation to develop multiple-dose regimens for drugs exhibiting nonlinear elimination kinetics.
    Hepler CD; Prince RA
    Am J Hosp Pharm; 1980 Dec; 37(12):1631-5. PubMed ID: 7446538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The repeated one-point method for predicting dose sizes with irregular dosing intervals.
    Thompson GA; Ritschel WA
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):337-43. PubMed ID: 3733283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: cockcroft-gault and modification of diet in renal disease.
    Golik MV; Lawrence KR
    Pharmacotherapy; 2008 Sep; 28(9):1125-32. PubMed ID: 18752383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients.
    Ho KK; Bryson SM; Thiessen JJ; Greenberg ML; Einarson TR; Leson CL
    Pharmacotherapy; 1995; 15(6):754-64. PubMed ID: 8602384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
    Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
    Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a programmable hand-held calculator for clinical pharmacokinetics.
    Foster TS; Bourne DW
    Am J Hosp Pharm; 1977 Jan; 34(1):70-5. PubMed ID: 831476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simple electronic circuit for simulation of pharmacokinetic processes.
    Danek A; Poczatek J
    Arzneimittelforschung; 1976; 26(3):321-4. PubMed ID: 989320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Model building in pharmacokinetics/Part V: Simulation of blood level curves following repetitive dosing and their experimental verification (author's transl)].
    Hammer R; Bozler G; Heinzel G; Koss FW
    Arzneimittelforschung; 1977; 27(4a):928-31. PubMed ID: 577860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose equations without protein-binding parameters.
    Otozai K; Otaya H
    Int J Clin Pharmacol Biopharm; 1978 Oct; 16(10):463-6. PubMed ID: 700909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism-based concepts of size and maturity in pharmacokinetics.
    Anderson BJ; Holford NH
    Annu Rev Pharmacol Toxicol; 2008; 48():303-32. PubMed ID: 17914927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Method for controlled establishment of steady-state plasma levels through multiple dosing.
    Weiss M; Förster W
    Int J Clin Pharmacol Biopharm; 1978 Mar; 16(3):102-4. PubMed ID: 649225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug accumulation and dose finding (authors' transl)].
    Kurz H
    Arzneimittelforschung; 1977 Feb; 27(2A):250-3. PubMed ID: 577170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The time course of drug effects.
    Al-Sallami HS; Pavan Kumar VV; Landersdorfer CB; Bulitta JB; Duffull SB
    Pharm Stat; 2009; 8(3):176-85. PubMed ID: 19626596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.
    Klotz U
    Clin Pharmacokinet; 1976; 1(3):204-18. PubMed ID: 797498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A model-based approach to dose selection in early pediatric development.
    Cella M; Gorter de Vries F; Burger D; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2010 Mar; 87(3):294-302. PubMed ID: 20107435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.